Preexposure prophylaxis for HIV prevention

被引：32
作者：
Kelesidis T. [1 ]
Landovitz R.J. [2 ]
机构：
[1] Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA
[2] UCLA Center for Clinical AIDS Research and Education, David Geffen School of Medicine at UCLA, Los Angeles, CA 90035
来源：
Current HIV/AIDS Reports | 2011年 / 8卷 / 2期
关键词：
Antiretrovirals; HIV; Preexposure prophylaxis;
D O I：
10.1007/s11904-011-0078-4
中图分类号：
学科分类号：
摘要：
Reducing the incidence of HIV remains one of our greatest public health challenges. However, there is growing optimism that preexposure prophylaxis (PrEP) could have a major impact on preventing incident HIV infection. Recently presented data on the use of oral PrEP in men who have sex with men (MSM) have provided proof-of-principle for this strategy. Additional clinical trials are evaluating whether PrEP provides similar protection to risk groups other than MSM, such as heterosexual persons and injection drug users. Still unanswered questions include optimal dosing strategies, long-term safety, maximizing adherence and minimizing costs, addressing drug resistance in the face of PrEP failure, optimizing access, and assessing effects on risk behavior. Future implementation will be guided by the results of clinical trials in progress. This article provides a review of the data on the potential strengths and limitations of PrEP as an HIV prevention strategy, identifies challenges to implementation of this approach, and outlines knowledge gaps. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：94 / 103
页数：9
相关论文
共 56 条
  • [11] Dumond J.B., Yeh R.F., Patterson K.B., Corbett A.H., Jung B.H., Rezk N.L., Bridges A.S., Stewart P.W., Cohen M.S., Kashuba A.D.M., Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis, AIDS, 21, 14, pp. 1899-1907, (2007)
  • [12] Dumond J.B., Patterson K.B., Pecha A.L., Werner R.E., Andrews E., Damle B., Et al., Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women, J Acquir Immune Defic Syndr, 51, 5, pp. 546-553, (2009)
  • [13] Grant R.M., Antiretroviral agents used by HIV-uninfected persons for prevention: Pre- and postexposure prophylaxis, Clin Infect Dis, 50, SUPPL. 3, pp. 96-101, (2010)
  • [14] Miller C.J., Li Q., Abel K., Kim E.-Y., Ma Z.-M., Wietgrefe S., La Franco-Scheuch L., Compton L., Duan L., Shore M.D., Zupancic M., Busch M., Carlis J., Wolinksy S., Haase A.T., Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus, Journal of Virology, 79, 14, pp. 9217-9227, (2005)
  • [15] Garcia-Lerma J.G., Cong M.E., Mitchell J., Youngpairoj A.S., Zheng Q., Masciotra S., Et al., Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection, Sci Transl Med, 2, 14, (2010)
  • [16] Blum M.R., Chittick G.E., Begley J.A., Jian Zong, Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers, Journal of Clinical Pharmacology, 47, 6, pp. 751-759, (2007)
  • [17] Gandhi M., Benet L.Z., Bacchetti P., Kalinowski A., Anastos K., Wolfe A.R., Et al., Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women, J Acquir Immune Defic Syndr, 50, 5, pp. 482-491, (2009)
  • [18] Volmink J., Siegfried N.L., Van Der Merwe L., Brocklehurst P., Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection, Cochrane Database Syst Rev, 1, (2007)
  • [19] Hawkins T., Veikley W., St. Claire III R.L., Guyer B., Clark N., Kearney B.P., Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens, Journal of Acquired Immune Deficiency Syndromes, 39, 4, pp. 406-411, (2005)
  • [20] Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.-H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M., Identification and characterization
123456